Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceTWST -3.03%69 3-Year Share Buyback Ratio is -2.40 as of Jun. 2026. GuruFocus rates TWST with a GF Score™ of 69/100 and a GF Value™ of $53.11 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,188 Biotechnology companies, Twist Bioscience ranks better than 75.84% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Twist Bioscience's current 3-Year Share Buyback Ratio was -2.40%.
The historical rank and industry rank for Twist Bioscience's 3-Year Share Buyback Ratio or its related term are showing as below:
TWST'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -23 Med: -8.5 Max: -2.4
Current: -2.4
During the past 10 years, Twist Bioscience's highest 3-Year Share Buyback Ratio was -2.40%. The lowest was -23.00%. And the median was -8.50%.
TWST's 3-Year Share Buyback Ratio is ranked better than 75.84% of 1188
companies
in the Biotechnology industry
Industry Median: -11.85
vs TWST: -2.40
Twist Bioscience (NAS:TWST) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Twist Bioscience 3-Year Share Buyback Ratio Related Terms
TWST vs QGEN, RDNT, SHC: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Twist Bioscience's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Twist Bioscience's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's 3-Year Share Buyback Ratio falls into.
Twist Bioscience 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -2.40 mean?
Twist Bioscience (TWST) has a 3-Year Share Buyback Ratio of -2.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Twist Bioscience and its competitors. According to the industry distribution chart, Twist Bioscience ranks #287 out of 1188 companies in the Biotechnology industry, placing it in the top 24.2%.
Is Twist Bioscience's 3-Year Share Buyback Ratio too high?
Twist Bioscience's current 3-Year Share Buyback Ratio is -2.40. Based on the distribution chart, Twist Bioscience ranks #287 out of 1188 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's 3-Year Share Buyback Ratio compare to QGEN and RDNT?
According to the Biotechnology industry distribution chart, Twist Bioscience ranks #287 out of 1188 companies for 3-Year Share Buyback Ratio. This places Twist Bioscience in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Twist Bioscience and its competitors. Twist Bioscience's current 3-Year Share Buyback Ratio is -2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.11, compared to a current price of $124.72 — trading 134.8% above its estimated fair value. The current 3-Year Share Buyback Ratio is -2.40. Twist Bioscience's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Twist Bioscience (TWST), the current 3-Year Share Buyback Ratio is -2.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $124.72 is trading 134.8% above its estimated GF Value™ of $53.11.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
3-Year Share Buyback Ratio: -2.40
GF Value™: $53.11 vs. price of $124.72 (134.8% above fair value)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
